<DOC>
	<DOCNO>NCT00224068</DOCNO>
	<brief_summary>This study evaluate safety efficacy FerrlecitÂ® ( ferric gluconate ; form intravenous iron ) ferrous sulfate ( form oral iron ) improve response epoetin alfa among anemic cancer patient receive chemotherapy .</brief_summary>
	<brief_title>Effect Iron Therapy Adjunct Epoetin Alfa Anemia Cancer Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Diagnosis nonmyeloid malignancy Moderate severe anemia Adequate iron store measure either TSAT ferritin About start cycle chemotherapy Eligible epoetin alfa therapy Highly elevate TSAT ferritin Recent transfusion , epoetin alfa , darbepoetin intravenous iron Medical condition would confound efficacy evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Iron deficiency</keyword>
	<keyword>Sodium ferric gluconate</keyword>
	<keyword>anemia</keyword>
	<keyword>cancer chemotherapy</keyword>
	<keyword>epoetin alfa</keyword>
	<keyword>Anemia/drug therapy</keyword>
	<keyword>Anemia , Iron-Deficiency/drug therapy/etiology</keyword>
	<keyword>Hematinics/administration &amp; dosage/pharmacology</keyword>
	<keyword>Antineoplastic Agents/adverse effect</keyword>
	<keyword>Erythropoietin , Recombinant/therapeutic use/adverse effect</keyword>
</DOC>